Thomas Frank E made one open market purchase of Larimar Therapeutics, Inc. ($LRMR) shares worth $25,000 in the last 365 days, most recently on February 27, 2026. This ranks 3606th among nearly 5,000 insiders, well below the average buy of $1.46 million across 3.3 transactions. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 27, 2026 | Larimar Therapeutics, Inc. | $LRMR | THOMAS FRANK E | Not found | P | Common Stock | 5000 | $5.00 | 7,000.0000 | 85,590,392 | 250.00% | 0.01% |
| June 12, 2025 | Spero Therapeutics, Inc. | $SPRO | THOMAS FRANK E | Not found | A | Common Stock | 20000 | $0.00 | 75,000.0000 | 55,900,641 | 36.36% | 0.04% |
| May 13, 2025 | Larimar Therapeutics, Inc. | $LRMR | THOMAS FRANK E | Director | A | Stock Option (Right to Buy) | 19000 | $0.00 | 19,000.0000 | 63,815,065 | 9999.99% | 0.03% |
| May 29, 2024 | Larimar Therapeutics, Inc. | $LRMR | THOMAS FRANK E | Director | A | Stock Option (Right to Buy) | 19000 | $0.00 | 19,000.0000 | 43,909,069 | 9999.99% | 0.04% |
| May 29, 2024 | Spero Therapeutics, Inc. | $SPRO | THOMAS FRANK E | Not found | A | Common Stock | 20000 | $0.00 | 55,000.0000 | 0 | 57.14% | 0.00% |
| Feb. 14, 2024 | Larimar Therapeutics, Inc. | $LRMR | THOMAS FRANK E | Director | P | Common Stock | 2000 | $11.00 | 2,000.0000 | 43,909,069 | 9999.99% | 0.00% |
| Oct. 5, 2023 | Spero Therapeutics, Inc. | $SPRO | THOMAS FRANK E | Not found | A | Common Stock | 20000 | $0.00 | 35,000.0000 | 0 | 133.33% | 0.00% |